- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.04. | AEON Biopharma Inc: AEON Biopharma Sets Annual Shareholder Meeting | 3 | GlobeNewswire (USA) | ||
| 03.04. | AEON Biopharma receives additional NYSE American non-compliance notice | 2 | Seeking Alpha | ||
| 03.04. | AEON Biopharma Inc: AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | 1 | GlobeNewswire (USA) | ||
| AEON BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 03.04. | AEON Biopharma Inc: AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards | 372 | GlobeNewswire (Europe) | IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar... ► Artikel lesen | |
| 30.03. | AEON Biopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | AEON Biopharma reports biosimilar progress, secures financing | 1 | Investing.com | ||
| 30.03. | AEON Biopharma Inc: AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program | 163 | GlobeNewswire (Europe) | - Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX - - Reported positive FDA BPD Type 2a... ► Artikel lesen | |
| 25.03. | AEON Biopharma receives FDA feedback on botulinum toxin biosimilar | 3 | Investing.com | ||
| 09.03. | AEON Biopharma names John Bencich as chief financial officer | 2 | Investing.com | ||
| 09.03. | AEON Biopharma beruft John Bencich zum neuen Finanzvorstand | 2 | Investing.com Deutsch | ||
| 09.03. | AEON Biopharma Inc: AEON Biopharma Appoints John Bencich as Chief Financial Officer | 847 | GlobeNewswire (Europe) | IRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar... ► Artikel lesen | |
| 09.03. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.01. | AEON Biopharma Completes BPD Type 2a Meeting With FDA | - | RTTNews | ||
| 21.01. | Aeon Biopharma: Aktie gibt nach FDA-Gespräch und Umschuldung nach | 1 | Investing.com Deutsch | ||
| 21.01. | AEON Biopharma Inc: AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions | 652 | GlobeNewswire (Europe) | - AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes - - Separately, AEON shareholders today... ► Artikel lesen | |
| 21.01. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.01. | AEON Biopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.12.25 | AEON Biopharma Inc: AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | 1 | GlobeNewswire (USA) | ||
| 15.12.25 | AEON Biopharma announces execution of exchange agreement with Daewoong Pharmaceutical | 1 | Seeking Alpha | ||
| 15.12.25 | AEON Biopharma Inc: AEON Biopharma Announces Execution of Exchange Agreement with Daewoong | 701 | GlobeNewswire (Europe) | - AEON and Daewoong Pharmaceutical have executed definitive documentation to exchange $15 million of notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercise... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 39,120 | -0,18 % | Tempus AI nach erneutem Kursrückgang: Risiko-Chance-Profil spitzt sich nach Q1-Zahlen weiter zu | Tempus AI hat nach den Q1-Zahlen erneut einen Kursrückgang verzeichnet, der nach Einschätzung eines Beitrags auf Seeking Alpha ein attraktives Chance-Risiko-Profil für risikobereite Anleger eröffnen... ► Artikel lesen | |
| ABIVAX | 103,00 | -0,77 % | EQS-News: ABIVAX: Abivax Announces Results of its May 11, 2026 Annual General Meeting | EQS-News: ABIVAX
/ Key word(s): AGM/EGM
Abivax Announces Results of its May 11, 2026 Annual General Meeting
11.05.2026 / 22:05 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| ALTERITY THERAPEUTICS | 0,006 | 0,00 % | ALTERITY THERAPEUTICS LIMITED: Corporate Presentation May 2026 | ||
| APTEVO THERAPEUTICS | 4,750 | -0,21 % | Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection | Mipletamig continues to perform, delivers 87% clinical benefit and 81% remission in frontline AML, with no CRS in frontline patientsExecutive leadership transition complete. Jeff Lamothe appointed CEO... ► Artikel lesen | |
| BIOCURE TECHNOLOGY | 0,018 | 0,00 % | Biocure Technology Inc (2): Biocure adopts semi-annual financial reporting | ||
| QIAGEN | 28,350 | -1,56 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Qiagen nach endgültigen Quartalszahlen auf "Equal Weight" mit einem Kursziel von 38 US-Dollar belassen. Analyst... ► Artikel lesen | |
| EVOTEC | 4,540 | -10,63 % | Mit guten Konzepten und Entspannung im Nahost-Konflikt voran! MustGrow, K+S, Evotec und Novo Nordisk im Fokus | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Was für eine Nachricht: Einigung zwischen USA und dem Iran - Märkte plus 2 % in nur 1 Minute! So schnell kann es gehen. Für Investoren... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,220 | 0,00 % | H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) | ||
| TARSUS PHARMACEUTICALS | 64,66 | 0,00 % | Tarsus reiterates 2026 net product sales guidance of $670M-$700M as XDEMVY posts $145.4M in Q1 sales | ||
| BICARA THERAPEUTICS | 20,990 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,690 | 0,00 % | Arcutis Q1 2026: Umsatz steigt um 65 %, doch Expansionskosten führen zu höheren Verlusten | ||
| PRAXIS PRECISION MEDICINES | 346,46 | -0,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,330 | 0,00 % | Allogene Therapeutics Q1 2026 Earnings Call Transcript | ||
| TANGO THERAPEUTICS | 25,510 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | ||
| C4 THERAPEUTICS | 3,660 | -0,54 % | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab... ► Artikel lesen |
AEON BIOPHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,823 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AEON BIOPHARMA INC finden Sie auf Wallstreet Online.